Paul M. Kinsella

Experience

M&A matters include representing:

• Acceleron in its sale to Merck ($11.5 billion)
• Wright Medical in its sale to Stryker ($5.4 billion)
• TESARO in its sale to GSK ($5.1 billion)
• NxStage in its sale to Fresenius ($2.0 billion)
• Synageva in its sale to Alexion ($8.9 billion)
• Cubist in its sale to Merck ($9.5 billion)
• Genzyme in its sale to Sanofi ($20.1 billion and contingent value rights)
• Javelin in its sale to Hospira, which, after Javelin initiated litigation, closed on its original terms despite emergence of a contamination issue and which involved Hospira topping a merger agreement between Javelin and Myriad
• Pfizer in its acquisitions of Medivation ($14 billion), in which Pfizer prevailed in an auction triggered by an unsolicited bid by another pharmaceutical company; Hospira ($17 billion); Trillium ($2.3 billion); and Arena ($6.7 billion)
• Shire in its acquisitions of Baxalta ($32 billion), which commenced with an unsolicited public proposal shortly following Baxalta’s spin-off from Baxter, and Dyax ($5.9 billion)
• CIRCOR in its successful defense against a hostile tender offer

Capital markets matters include representing:

• Novavax in $2.5  billion in equity and convertible note offerings
• Sarepta in $3.0 billion in equity and convertible note offerings
• TransMedics in its IPO and a follow-on equity offering
• Ironwood in its IPO, follow-on equity offerings, and spin-off of Cyclerion
• Zoetis in the exchange of Zoetis stock ($12.9 billion) for Pfizer stock to split-off Zoetis from Pfizer
• The lead underwriters in the Vigil Neuroscience IPO
• The lead underwriters in the Entrada Therapeutics IPO
• The lead underwriters in a $6.7 billion secondary offering of Regeneron common stock and a $2.0 billion Regeneron investment grade debt offering
• The lead underwriters in the Elanco Animal Health IPO ($1.7 billion) and the dealer managers in the exchange of Elanco stock for Lilly stock ($8.6 billion)